Current Report Filing (8-k)
February 12 2019 - 6:11AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF
THE SECURITIES EXCHANGE ACT OF 1934
February
12, 2019 (February 11, 2019)
Date
of Report (Date of earliest event reported)
ELITE
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
001-15697
|
|
22-3542636
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
165
Ludlow Avenue, Northvale, New Jersey 07647
(Address
of principal executive offices)
(201)
750-2646
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item
2.02.
|
Results
of Operations and Financial Condition.
|
On
February 11, 2019, Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) filed its quarterly report on Form
10-Q for the quarter ended December 31, 2018 and, thereafter, issued a press release announcing its financial results for that
quarter. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
As
noted in the press release, the Company will host a conference call at 11:30 AM Eastern Standard Time (EST) on Tuesday, February
12, 2019, to provide a general business update. Elite will respond to various stockholder questions submitted prior to the call.
Conference
Call Information
Date:
|
Tuesday,
February 12, 2019
|
Time:
|
11:30
AM EST
|
Dial-in
numbers:
|
1-800-346-7359
(domestic)
|
|
1-973-528-0008
(international)
|
Conference
number:
|
98840
|
Questions:
|
dianne@elitepharma.com
by 7:00 PM EST on Monday, February 11, 2019
|
Audio
Replay:
|
https://elite.irpass.com/events_presentations
|
Item
7.01 Regulation FD Disclosure.
The
information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report
on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,”
Item 7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such,
the information (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section,
nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless
of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing.
This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required
to be disclosed solely to satisfy the requirements of Regulation FD.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated: February 12, 2019
|
ELITE PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Nasrat Hakim
|
|
|
Nasrat Hakim, President and CEO
|
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Oct 2023 to Oct 2024